[go: up one dir, main page]

WO2001046697A3 - Identification, assessment, prevention, and therapy of breast cancer - Google Patents

Identification, assessment, prevention, and therapy of breast cancer Download PDF

Info

Publication number
WO2001046697A3
WO2001046697A3 PCT/US2000/035214 US0035214W WO0146697A3 WO 2001046697 A3 WO2001046697 A3 WO 2001046697A3 US 0035214 W US0035214 W US 0035214W WO 0146697 A3 WO0146697 A3 WO 0146697A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
assessment
therapy
prevention
identification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/035214
Other languages
French (fr)
Other versions
WO2001046697A2 (en
Inventor
James Lillie
Adam Palermo
Youzhen Wang
Kathleen Steinmann
Josh Elias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Priority to AU25969/01A priority Critical patent/AU2596901A/en
Publication of WO2001046697A2 publication Critical patent/WO2001046697A2/en
Publication of WO2001046697A3 publication Critical patent/WO2001046697A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to compositions, kits and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of breast cancer.
PCT/US2000/035214 1999-12-21 2000-12-21 Identification, assessment, prevention, and therapy of breast cancer Ceased WO2001046697A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU25969/01A AU2596901A (en) 1999-12-21 2000-12-21 Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US17140699P 1999-12-21 1999-12-21
US60/171,406 1999-12-21
US17642300P 2000-01-14 2000-01-14
US60/176,423 2000-01-14
US19047100P 2000-03-17 2000-03-17
US60/190,471 2000-03-17
US19348200P 2000-03-29 2000-03-29
US60/193,482 2000-03-29
US20523100P 2000-05-15 2000-05-15
US60/205,231 2000-05-15
US21323600P 2000-06-20 2000-06-20
US60/213,236 2000-06-20
US21986500P 2000-07-20 2000-07-20
US60/219,865 2000-07-20

Publications (2)

Publication Number Publication Date
WO2001046697A2 WO2001046697A2 (en) 2001-06-28
WO2001046697A3 true WO2001046697A3 (en) 2002-01-10

Family

ID=27569123

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/035214 Ceased WO2001046697A2 (en) 1999-12-21 2000-12-21 Identification, assessment, prevention, and therapy of breast cancer

Country Status (2)

Country Link
AU (1) AU2596901A (en)
WO (1) WO2001046697A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402660B2 (en) 2000-08-02 2008-07-22 The Johns Hopkins University Endothelial cell expression patterns
ATE503023T1 (en) 2001-06-18 2011-04-15 Rosetta Inpharmatics Llc DIAGNOSIS AND PROGNOSIS OF BREAST CANCER PATIENTS
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
AT410945B (en) * 2001-06-27 2003-08-25 Burkhard Dr Jansen Diagnosis of multiple sclerosis or tumors, by detecting absence of wild-type stem cell factor-apoptosis response gene, or the derived protein, also new nucleic acids
WO2003087122A2 (en) * 2002-04-12 2003-10-23 Molecular Engines Laboratories Sequences involved in the phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses, and the use of the same as medicaments
WO2003087154A2 (en) * 2002-04-12 2003-10-23 Molecular Engines Laboratories Sequences involved in the phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses, and the use of the same as medicaments
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US8940488B2 (en) 2004-03-31 2015-01-27 Hiroyuki Aburatani Cancer diagnosis and treatment of cancer using anti-robo 1 antibody
WO2005095981A1 (en) 2004-03-31 2005-10-13 Perseus Proteomics Inc. Cancer diagnosis and treatment using anti-robo1 antibody
MX2008002101A (en) 2005-08-12 2008-04-19 Schering Corp Mcp1 fusions.
JP5117765B2 (en) 2007-05-28 2013-01-16 国立大学法人 東京大学 Tumor diagnostic agent for PET containing anti-ROBO1 antibody
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775620A (en) * 1984-01-06 1988-10-04 The Regents Of The University Of California Cytokeratin tumor markers and assays for their detection
US5188964A (en) * 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
WO1997046884A1 (en) * 1996-06-05 1997-12-11 Matritech, Inc. Materials and methods for detection of breast cancer
WO1998008947A1 (en) * 1995-12-19 1998-03-05 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhancement of dna immunization through the use of cytokines
WO1998035229A1 (en) * 1997-02-07 1998-08-13 Macquarie Research Ltd. Diagnosis of disease using tears
WO1999032625A2 (en) * 1997-12-19 1999-07-01 The University Of Michigan Nucleotide and protein sequence of mammastatin and methods of use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775620A (en) * 1984-01-06 1988-10-04 The Regents Of The University Of California Cytokeratin tumor markers and assays for their detection
US5188964A (en) * 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
WO1998008947A1 (en) * 1995-12-19 1998-03-05 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhancement of dna immunization through the use of cytokines
WO1997046884A1 (en) * 1996-06-05 1997-12-11 Matritech, Inc. Materials and methods for detection of breast cancer
WO1998035229A1 (en) * 1997-02-07 1998-08-13 Macquarie Research Ltd. Diagnosis of disease using tears
WO1999032625A2 (en) * 1997-12-19 1999-07-01 The University Of Michigan Nucleotide and protein sequence of mammastatin and methods of use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BERNARDINI ET AL: "Identification of the CC chemokines TARC and macrophage inflammatory protein-1 beta as novel functional ligands for the CCR8 receptor", EUROPEAN JOURNAL OF IMMUNOLOGY,DE,WEINHEIM, vol. 28, no. 2, 1 February 1998 (1998-02-01), pages 582 - 588, XP002092743, ISSN: 0014-2980 *
BERNSTEIN S H ET AL: "A randomized phase II study of BB-10010: a variant of human macrophage inflammatory protein -1alpha for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer.", BRITISH JOURNAL OF HAEMATOLOGY, (1997 DEC) 99 (4) 888-95., XP001011409 *
DATABASE SWISS-PROT 1 January 1990 (1990-01-01), XP002171087 *
TANAKA, YOSHIYA (1) ET AL: "Constitutive up-regulation of integrin-mediated adhesion of tumor-infiltrating lymphocytes to osteoblasts and bone marrow-derived stromal cells.", CANCER RESEARCH, (SEPT. 15, 1998) VOL. 58, NO. 18, PP. 4138-4145., XP001010064 *
TEDLA N ET AL: "Abundant expresssion of chemokines in malignant and infective human lymphadenopathies", CYTOKINE,ACADEMIC PRESS LTD, PHILADELPHIA, PA,US, vol. 11, no. 7, July 1999 (1999-07-01), pages 531 - 540, XP002166395, ISSN: 1043-4666 *
WANG J M ET AL: "Chemokines and their role in tumor growth and metastasis", JOURNAL OF IMMUNOLOGICAL METHODS,NL,ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, vol. 220, no. 1-2, 1 November 1998 (1998-11-01), pages 1 - 17, XP004144097, ISSN: 0022-1759 *

Also Published As

Publication number Publication date
AU2596901A (en) 2001-07-03
WO2001046697A2 (en) 2001-06-28

Similar Documents

Publication Publication Date Title
WO2001051628A3 (en) Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2001053836A3 (en) Identification, assessment, prevention, and therapy of prostate cancer
WO2001042467A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2001070979A3 (en) Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
WO2001060860A3 (en) Genes differentially expressed in human prostate cancer and their use
WO2001086002A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
AU2002322280A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2001018542A3 (en) Identification, assessment, prevention, and therapy of ovarian cancer
AU2002324451A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
WO2003060465A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
WO2001046697A3 (en) Identification, assessment, prevention, and therapy of breast cancer
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
WO2005032328A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
WO2002102306A8 (en) Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
WO2002085298A3 (en) Method for detecting breast cancer cells
WO2002046765A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
WO2005118869A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
WO2001042792A3 (en) Diagnosis of cervical cancer using marker proteins
EP1653975A4 (en) COMPOSITIONS AND METHODS FOR TREATING, PREVENTING AND / OR MITIGATING CANCERS, THE APPEARANCE OF CANCER OR SYMPTOMS OF CANCER
AU2001290949A1 (en) Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma
AU2001238493A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP